MOTS-c research: a mitochondrial peptide that declines with age
MOTS-c is encoded by mitochondrial DNA, falls in circulation with age, and rises after aerobic exercise. Most functional evidence still comes from aged mice.
Most research peptides are modeled on proteins encoded in the cell nucleus. MOTS-c is different. Discovered in 2015, it is a 16-amino-acid peptide encoded directly by mitochondrial DNA, and its circulating levels fall with age. One everyday activity, aerobic exercise, reliably raises it.
Mechanism: AMPK through the folate cycle
MOTS-c acts on AMPK, a core regulator of cellular energy metabolism. It reaches that pathway through the folate cycle, which makes it mechanistically distinct from peptides that work by binding a cell-surface receptor. The research areas it is studied for include:
- AMPK activation
- Insulin sensitivity and glucose metabolism
- Mitochondrial stress response through the Nrf2 pathway
- Exercise-induced signaling
- Immune regulation, including T-cell activity
- Skeletal muscle homeostasis
How MOTS-c changes across age groups
A human cross-sectional study compared three cohorts: ages 18 to 30, 45 to 55, and 70 to 81. Circulating MOTS-c was highest in the youngest group, significantly lower in the 45 to 55 group, and lower still in the 70 to 81 group.
The same study found something that complicates the simple story. Skeletal muscle expression of MOTS-c was about 1.5 times higher in the oldest group than in young adults. Circulating levels and tissue levels moved in opposite directions, and that tissue-specific divergence is still being explained. The decline is real in plasma, but it is not a clean decline everywhere.
Exercise and the mimetic label
Acute aerobic exercise raises circulating MOTS-c in humans. That observation led researchers to describe it as an exercise mimetic signal, a molecule whose activity overlaps with some of the metabolic signaling that exercise produces.
The limits of the evidence
Human research on MOTS-c is largely observational rather than interventional. The functional findings, such as reversal of physical decline and improved insulin sensitivity, come from studies in aged mice and have not been replicated in humans. Safety in an administered context has not been established, and a related analog showed persistent local site reactions in a short-term trial.
MOTS-c was also part of the FDA Pharmacy Compounding Advisory Committee meeting on July 23 and 24, 2026, which reviewed it for the 503A bulk substances list and voted 7 to 5 to recommend it. That was its first formal evaluation. It is an active regulatory process, and its status may change after this article.
Sources
- Increased expression of the mitochondrial derived peptide, MOTS-c, in skeletal muscle of healthy aging men is associated with myofiber composition. Aging (Albany NY), 2020.
- Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging. NCBI PMC9854231.
- FDA Pharmacy Compounding Advisory Committee, July 23 to 24, 2026 meeting, MOTS-c 503A bulk substance review.